26th IFPMA assembly – panel discussion I
Geneva, October 31, 2012
Panel I: “Innovation Today: Treading New Ground to Meet Global Health Needs”
Cary Adams, CEO, Union for International Cancer Control
Nigel Darby, Vice President of Biotechnologies, Chief Technology Officer GE Healthcare
David Khayat, Professor and Head of Medical Oncology, Pitié-Salpêtrière Hospital
John Lechleiter, Chairman, President, and CEO, Eli Lilly & Company
Mary Lou Valdez, Associate Commissioner for International Programs, U.S. Food and Drug Administration
About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations across the globe. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. The industry’s two million employees discover, develop, and deliver medicines and vaccines that advance global health.
Learn more
Related news and resources
WHO Intergovernmental Negotiating Body (INB) intersessional briefing on the “Transfer of technology and know-how”
On 20 March, IFPMA delivered a shortened version of the below statement at the WHO INB intersessional briefing on “Article 7: Access to technology: promoting sustainable and equitably distributed production and transfer of technology and know-how” of the WHO convention, agreement, or other international instrument on pandemic prevention, preparedness, and response (“WHO CA+”).
Read moreStatement to the IHR Review Committee on amendments to the International Health Regulations
IFPMA encourages the consistent coordination of the INB and IHR processes to ensure a non-duplicative, fit-for-purpose outcome for all.
Read moreImpact of a waiver of intellectual property rights for COVID-19 therapeutics
As WTO Member States continue to discuss an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics, latest evidence and data published today explains what the consequences of such a waiver would have on industry’s ability to fight the COVID-19 pandemic.
Read more